Cardiology Acute Coronary Syndromes and Lipid research

Associate Professor James Shaw has numerous years of experience in clinical trials and research in Cardiology. His commitment to advancing the field of Cardiology is reflected in their active involvement in publishing research findings in reputable medical journals. Dr Shaw provides patients both inpatients and outpatients at Alfred Health an opportunity to gain access to new research treatments before they are widely available. Ensuring his patients an opportunity to partake in clinical trial or studies as another avenue of clinical treatment and care is a key passion of Dr Shaw’s. Having updated and emerging practices is a key focus for our cohort of patients. These projects consist of both pharmaceutical sponsored trials and internal investigator-initiated studies.

Dr James Shaw and the clinical trial team ensure patients receive exceptional high quality care. Some of our current trials are Prevail (Obicetrapid), treatments that reduce LDL levels and increasing HDL levels in a patient cholesterol profile, thus reducing future incidents in ACS events. Core (Olezarsen) new treatments in hypertriglyceridemia where traditional therapies have not been sufficient. SOS – AMI novel antiplatelet agent.

As we move into 2025, we look forward to the launch of more groundbreaking clinical trials that will continue to shape the future of cardiology research and patient care

Research Focus

The key areas of focus for upcoming cardiology trials in 2025 will be, Acute Coronary Syndrome (ACS), and Lipid management.

With a focus on is an investigational weight loss medication. It is a bispecific antibody-peptide conjugate designed to target both the GLP-1 receptor and the GIP receptor, aiming to enhance weight loss efficacy compared to existing treatments on patient with cardiovascular disease.

 An investigational, subcutaneously administered P2Y₁₂ receptor antagonist being developed for the rapid treatment and prevention of acute myocardial infarction (AMI). These areas are critical for advancing treatment options and improving patient outcomes in cardiovascular care."

Novel agents that are a liposome-encapsulated form of rosuvastatin, which is a statin approved for lowering cholesterol and slowing atherosclerosis progression. The liposome is designed to actively target CD44 receptors, which are upregulated in AS plaques, thereby delivering rosuvastatin directly to the plaques and enhancing its therapeutic effects.​

A novel agent that is a small interfering RNA (siRNA) conjugated to N-acetylgalactosamine (GalNAc), which facilitates liver-specific delivery. It works by silencing the LPA gene, leading to a reduction in the production of apolipoprotein(a) [apo(a)], the protein component of Lp(a). This mechanism effectively lowers Lp(a) levels in the bloodstream. ​

We are delighted to be able to offer patients optimal and additional care in our speciality field. Our research participants experience improved health outcomes.

Our partners

Baker Heart & Diabetes Institute